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Abstract Cholecalciferol (D3) supplementation results in
variable increases in serum 25(OH)D3 levels, however, the
influence of genetic polymorphisms on these variable re-
sponses is unclear. We measured serum 25(OH)D3, 24,25
(OH)2D3, 1,25(OH)2D3 and VDBP levels in 50 colorectal
cancer (CRC) patients before and during 2,000 IU daily oral
D3 supplementation for six months and in 263 archived
CRC serum samples. Serum PTH levels and PBMC 24-
OHase activity were also measured during D3 supplementa-
tion. TagSNPs in CYP2R1, CYP27A1, CYP27B1, CYP24A1,
VDR, and GC genes were genotyped in all patients, and the
association between these SNPs and serum vitamin D3
metabolites levels before and after D3 supplementation
was analyzed. The mean baseline serum 25(OH)D3 level
was less than 32 ng/mL in 65 % of the 313 CRC patients. In
the 50 patients receiving D3 supplementation, serum levels
of 25(OH)D3 increased (p=0.008), PTH decreased (p=
0.036) and 24,25(OH)2D3, 1,25(OH)2D3, VDBP levels and
PBMC 24-OHase activity were unchanged. GC SNP
rs222016 was associated with high 25(OH)D3 and 1,25
(OH)2D3 levels at baseline while rs4588 and rs2282679
were associated with lower 25(OH)D3 and 1,25(OH)2D3
levels both before and after D3 supplementation. CYP2R1
rs12794714 and rs10500804 SNPs were significantly asso-
ciated with low 25(OH)D3 levels after supplementation but
not with baseline 25(OH)D3. Our results show that D3
supplementation increased 25(OH)D3 levels in all patients.
GC rs4588 and rs2283679 SNPs were associated with in-
creased risk of vitamin D3 insufficiency and suboptimal
increase in 25(OH)D3 levels after D3 supplementation.
Individuals with these genotypes may require higher D3
supplementation doses to achieve vitamin D3 sufficiency.
Introduction
Serum 25(OH)D3 level is the accepted indicator of vitamin D3
sufficiency in humans. Since dietary sources of vitamin D3 are
limited, the major cause of human vitamin D3 insufficiency
(defined as serum 25(OH)D3<32 ng/mL) is inadequate expo-
sure to the sun [1, 2]. Several factors including living at higher
latitudes, cultural practices limiting skin exposure to sunlight,
advanced age, obesity, and dark skin pigmentation are associ-
atedwith low serum 25(OH)D3 levels [3–5].We have reported
that recent cancer chemotherapy may be a predisposing factor
for vitamin D3 deficiency in CRC patients [6].
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The clinical significance of vitamin D insufficiency in pa-
tients with established colorectal cancer, especially those with
metastatic disease, is unclear. However, the association be-
tween vitamin D3 insufficiency and an increased risk of devel-
oping colorectal cancer is supported by several case–control
studies [7, 8]. In a Norwegian study, higher colorectal cancer
mortality was observed when the diagnosis of colon cancer
wasmade duringwinter or spring (lower 25(OH)D3) compared
to summer and autumn (higher 25(OH)D3) [9]. Furthermore,
the Nurse’s Health Study (NHS) and Health Professionals
follow-up study showed that the lowest risk of death (adjusted
for other variables) from CRC disease was seen in patients in
the highest quartile of serum 25(OH)D3 levels [10].
Polymorphisms in several vitamin D genes (CYP2R1,
CYP27A1, CYP27B1, CYP24A1, VDBP and VDR) have been
associated several human diseases, including CRC [11]. The
proteins encoded by these genes include CYP2R1 and
CYP27A1 which convert vitamin D to 25(OH)D3. 25(OH)
D3 is then converted by CYP27B1 to 1,25(OH)2D3, the bio-
logically most active form of vitamin D3. CYP24A1 converts
25(OH)D3 and 1,25(OH)2D3 to 24, 25(OH)2D3 and 1, 24, 25
(OH)2D3, respectively, which are less active. Vitamin D bind-
ing protein (VDBP), encoded by GC (group-specific compo-
nent), is the transporter of vitamin D3 metabolites in
circulation while VDR, a nuclear hormone receptor, mediates
the action of vitamin D3 by transcriptionally controlling the
expression of hormone sensitive genes. Studies show signifi-
cant association between single nucleotide polymorphisms
(SNP) in the GC (rs2282679), DHCR7 (rs12785878), and
CYP2R1 (rs10741657) genes and serum 25(OH)D3 levels
[12, 13]. There are reported associations between 25(OH)D3
levels and SNPs in GC (rs4588 and rs7041), VDR
(rs10735810) and CYP27B1 (rs10877012) genes [14, 15].
The AA genotype of VDR rs1544410 has been associated
with higher serum 1,25(OH)2D3 levels compared to the GG
genotype [16]. Reports on the effect of D3 supplementation on
the associations between polymorphisms in the vitamin D3
pathway genes and serum 25(OH)D3, 24,25(OH)2D3 and 1,25
(OH)2D3levels are few. A suboptimal response to D3 supple-
mentation was associated with GC rs4588 SNP in healthy
adults [17]. Comprehensive studies to identify SNPs in the
vitamin D3 metabolizing and signaling pathway genes that are
associated with response to D3 supplementation will provide
insight into factors influencing vitamin D health and informa-
tion on the planning of prospective cancer chemoprevention
and therapeutic clinical trials.
In this study, we measured serum vitamin D metabolite
levels (25(OH)D3, 24,25(OH)2D3, 1,25(OH)2D3) together
with vitamin D binding protein (VDBP ) levels in 313
CRC patient samples and correlated these measures with
SNPs in the major vitamin D3 metabolizing and signaling
pathway genes at baseline and with vitamin D sufficiency.
We also tested for associations between these SNPs and
changes in the serum vitamin D3 metabolites levels in a
subset of CRC patients receiving a fixed dose of 2,000 IU
of oral cholecalciferol daily for 6 months.
Materials and Methods
Research Blood Sample Collections and Storage
Archived blood samples of 263 CRC patients were obtained
from Roswell Park Cancer Institute (RPCI) Data Bank and
BioRepository. Blood samples were also collected prospec-
tively from RPCI CRC patients enrolled in a study of fixed
oral dose of 2000 IU of cholecalciferol (D3) once daily for
6 months. Eligibility criteria, baseline and follow-up clinical
evaluation of the patients enrolled in the D3 supplementation
protocol has been published [18]. Protocols for these studies
were both approved by the RPCI Institutional Review Board
(IRB) prior to starting these studies.
Serum samples for vitamin D3 metabolite and PTH level
measurements were collected before treatment and on days
14, 30, 60, 90, and 180 of D3 supplementation and stored at
−80 °C until assayed. VDBP was measured in samples
collected at baseline and on day 90 only. Baseline blood
samples collected in EDTA tubes and stored at −80 °C was
used for DNA isolation. Serum samples for PTH assay were
stored at −80 °C and were assayed within 12 months of
samples collection. PTH levels in archived serum samples
were not measured.
Analytical Assays
Serum 25(OH)D3, 24,25(OH)2D3, and 1,25(OH)2D3 Assays
A high-performance liquid chromatographic assay with tan-
dem mass spectrometric detection (LC/MS/MS) was used to
simultaneously measure 24,25(OH)2D3 and 25(OH)D3 in
0.25 mL of human serum sample. Stable-isotope labeled
25-Hydroxyvitamin D3-(26,26,27,27,27-d6) was the inter-
nal standard [19, 20]. Sample preparation for LC/MS/MS
analysis included liquid–liquid extraction using methanol
and chloroform (1:3v/v). The dried organic layer containing
24,25(OH)2D3 and 25(OH)D3 was reconstituted in 60 μL of
methanol (MeOH)/water (60/40 %) and 25 μL volumes
were injected and separated on reverse phase dC-18 column
(Waters Corp) using MeOH/water gradient (0 min 80 %
MeOH, 3 min 99 % MeOH, 10 min 99 % MeOH,10.1 min
80 % MeOH, 15 min 80 % MeOH at flow rate of
220 μL/min). TSQ Quantum ULTRA mass spectrometer
with positive atmospheric pressure chemical ionization
(APCI) source was used to monitor 24,25(OH)2D3,
25(OH)D3 and the internal standard at transitions of m/z
399>127, 383>365 and 389>371 respectively. The assay
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lower limit of detection were 0.25 ng/mL for both
24,25(OH)2D3 and 25(OH)D3. Serum 25(OH)D3 levels
measured by our LC/MS/MS method were 10–17 % higher
than the values obtained using DiaSorin 25-hydroxyvitamin
D RIA kits. Serum 1,25(OH)2D3 levels were measured
using DiaSorin RIA kits as previously described [21].
Plasma PTH and VDBPAssays
Serum PTH levels were measured using biologically intact
hPTH 1–84 immunoradiometric Kits from DiaSorin
(Stilwell, MN). Quantitative determination of total serum
vitamin D binding proteins (VDBP) was performed using
K2314 VDBP ELISA kits from ALPCO immunoassays
(Salem, NH). Both assays were performed according to the
instructions supplied with kits.
24-Hydroxylase Activity Assay
PBMC 24-OHase activity was assayed as previously de-
scribed [22, 23]. The assay consisted of 2×106 PBMC (as
the 24-OHase enzyme source), and 0.5 μCi (110,000 dpm)
[3H]-25(OH)D3 as the substrate; total assay volume was
0.5 ml of buffer (0.19 M sucrose, 25 mM sodium succinate,
2 mM MgCl2, 1 mM EDTA and 20 mM HEPES), pH 7.4.
The reaction was initiated by the addition of substrate
followed by 30 min incubation at 37 °C. [3H]-25(OH)D3
oxidative metabolites were extracted by liquid–liquid parti-
tion, separated by HPLC and measured by liquid scintillation
counting of collected HPLC fractions. Radioactivity in the
fractions containing all 24-oxidative metabolites of 25(OH)
D3 were pooled and 24-OHase activity, normalized for varia-
tions in extraction efficiency, was calculated using the radio-
activity ratio of pooled 24-oxidative metabolites/total
radioactivity recovered and expressed as femtomoles per hour
per mg of protein.
Genotyping Assays
Genomic DNA was isolated from whole blood samples
using Flexi Gene DNA kits (Qiagen Inc, Valencio, CA).
The quality and quantity of DNA isolated was determined
using both Nanodrop (Thermo Scientific, Waltham, MA)
and PicoGreen (Molecular Probes Inc., Eugene, OR)
methods.
TagSNPs in CYP2R1, CYP27A1, CYP27B1, CYP24A1,
VDR and GC genes were selected from databases (NCBI;
HapMap) and from CYP24A1 re-sequenced data generated
in our laboratory from Caucasian DNA samples from the
Coreil Cell Repository (unpublished). Briefly, SNP genotype
datasets for Caucasians were loaded into the Haploview pro-
gram (version 4.0) (Broad Institute, MIT and Harvard,
Cambridge, MA, USA) and polymorphisms with frequencies
greater than 5 % were selected for haplotype analysis at an r2
threshold of 0.8. Haplotypes close to or greater than 2 % were
organized into single blocks from which haplotype tagSNPs
were derived. The tagger software was also used to generate
tagSNPs. Other websites used for tagSNPs selection included
NIEHS (http://snpinfo.niehs.nih.gov/snptag.htm) and GVS
(http://gvs.gs.washington.edu/GVS/). A total of 80 tagSNPs
were genotyped using the Sequenom MassArray platform
(Sequenon, San Diego, CA) in accordance with the
manufacturer’s instructions (http://www.sequenom.com/
seq-genotyping). Controls were included to ensure
genotyping accuracy in addition to genotyping approximately
10 % of the samples in duplicates.
Data Analysis
Patients with baseline serum 25(OH)D3 levels <20 ng/mL,
20–31.9 ng/mL and ≥32 ng/mL were considered to be
vitamin D3 deficient, insufficient and sufficient, respective-
ly. Free index (a measure of non-protein bound) 25(OH)
D3, 24,25 (OH)2D3 and 1,25(OH)2D3 were calculated as a
molar ratio of each vitamin D3 metabolite/VDBP.
Frequencies and relative frequencies were computed for
categorical variables and numeric variables were summa-
rized using mean, standard deviation, standard error of
mean, median and range as appropriate. Fisher’s exact
test was used to study the association between categorical
variables and the Wilcoxon rank sum test was used to
compare the groups’ numeric variables.
The generalized linear models with corresponding link
function and distribution of different response variables
were used to investigate the association between study vari-
ables and a set of variables for multivariate analysis. P<0.05
nominal significance level was used in all testing. All sta-
tistical analyses were done using SAS (version 9.1).
Association analysis of serum vitamin D3 metabolite
concentrations with SNPs were performed using general-
ized linear models. Logistic regression models were used
to measure SNP association analyses with sufficiency
status (insufficient/deficient vs. sufficient). For the D3
supplementation population, vitamin D3 metabolite levels
were log transformed and genotypes were coded as 0, 1,
and 2 for homozygous major, heterozygous and homo-
zygous minor genotypes, respectively. Due to small sam-
ple size of D3 supplementation group and rarity of minor
genotypes, the minor and heterozygous genotypes were
pooled and compared to major genotype (reference
group) for all SNPS. Models were adjusted for age,
sex, BMI, tumor stage, chemotherapy status and plasma
VDBP levels. The β-coefficients from the linear models
represent the quantitative change in plasma measures
with the addition of the minor allele. The β coefficients
from the logistic regression models reflect the increase in
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odds of deficiency (or sufficiency) with each additional
copy of the variant allele.
Results
Patient Characteristics, Baseline Serum Vitamin D3
Metabolite and VDBP Levels
Characteristics, including self-reported racial background,
of all 313 CRC patients, stratified into three vitamin status
categories (deficient, insufficient, and sufficient, based on
baseline serum 25(OH)D3 levels), are shown in Table 1;
69.1 % of the vitamin D3 sufficient patients had blood
samples collected in summer/fall compared to 52.2 % and
39.8 % for the insufficient and deficient patients, respective-
ly. Neither BMI nor other patient demographic characteris-
tics (gender, age, race, and tumor stage) showed significant
association with vitamin D3 status. Serum 24,25(OH)2D3
levels were significantly associated with baseline serum
25(OH)D3 levels (p<0.0001), whereas serum 1,25(OH)2D3
and VDBP levels were not.
Effect of D3 Supplementation on Serum Vitamin D3
Metabolites, PTH, VDBP Levels and PBMC 24-OHase
Activity
Time course of the changes in serum 25(OH)D3, 24,25
(OH)2D3, 1,25(OH)2D3, PTH and VDBP levels and PBMC
24-OHase activity during D3 supplementation are shown in
Fig. 1. The increase in 25(OH)2D3 attained equilibrium levels
by day 90; the largest percentage increase in 25(OH)D3 levels
was in the vitamin D3 deficient category (Fig. 1a). Similar
increases in 24,25(OH)2D3 levels were observed (Fig. 1b).
The 1,25(OH)2D3 levels also increased but remained within
the physiologic range of 20–100 pg/mL (Fig. 1c). Serum 25
(OH)D3 and 24,25(OH)2D3 levels at baseline and during D3
supplementation were linearly correlated (Fig. 1d). The cor-
relation between 25(OH)D3 and 1,25(OH)2D3, and between
24,25(OH)2D3 and 1,25(OH)2D3 serum levels are shown in
Fig. 1e and f, respectively.
A decrease in serum PTH levels was observed within
30 days of starting D3 supplementation and no further decrease
in PTH levels was observed from day 60 onwards (Fig. 2a). No
significant changes in PBMC 24-OHase activity and serum
Table 1 Demographic and serum vitamin D3 variables in CRC patients stratified by baseline serum vitamin D3 status
Characteristics/variables Baseline vitamin D3 status* p value
Deficient (N=88) Insufficient (N=115) Sufficient (N=110)
Age, years <40 4 4 9 0.44
40–49 13 24 12
50–59 26 26 32
60–69 29 37 34
≥70 15 25 23
Gender F 44 (50 %) 48 (41.7 %) 55 (50 %) 0.37
M 44 (50 %) 67 (58.3 %) 55 (50 %)
Race White 76 (86.4 %) 101 (87.8 %) 100 (90.9 %) 0.52
Black 8 (9.1 %) 12 (10.4 %) 6 (5.5 %)
Others 4 (4.5 %) 2 (1.7 %) 4 (3.6 %)
Tumor stage Early (I/II) 8 (9.1 %) 18 (15.8 %) 16 (14.7 %) 0.35
Advanced (III/IV) 80 (90.9 %) 96 (84.2 %) 93 (85.3 %)
Sample collection season Summer–Fall 35 (39.8 %) 60 (52.2 %) 76 (69.1 %) 0.004
Winter–Spring 53 (60.2 %) 55 (47.8 %) 34 (30.9 %)
BMI (kg/m2) <25 27 (30.7 %) 23 (21.3 %) 34 (33.0 %) 0.065
25–30 25 (28.4 %) 43 (39.8 %) 42 (40.8 %)
>30 36 (40.9 %) 42 (38.9 %) 27 (26.2 %)
Vitamin D binding protein (VDBP) (μg/mL) 354.1±77.6 357.8±75.0 387.3±102.4 0.079
D3 metabolites 25(OH)D3 (ng/mL) 14.4±4.0 25.7±3.4 38.8±5.9 Inference
24,25(OH)2D3(ng/ml) 0.4±0.3 1.0±0.7 2.2±2.1 <0.0001
1,25 (OH)2D3 (pg/mL) 53.0±16.2 53.5.4±15.1 54.2±15.4 0.46
For numerical variables statistics represented as mean±SD
For categorical variables statistics represented as frequency (% relative frequency)
*Definitions of vitamin D3 status categories are based on serum 25(OH)D3 levels
<20ng/mL=deficient, 20–31.9 ng/mL=insufficient and ≥32ng/mL=sufficient
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Fig. 1 Time course of the changes in serum 25(OH)D3 (panel a),
24,25(OH)2D3 (panel b), and 1,25(OH)2D3 (panel c) levels in vitamin
D3 deficient (filled circle), insufficient (open circle), and sufficient
(filled square) CRC patients receiving 2000IU of oral cholecalciferol
daily. Vitamin D3 status stratification based on baseline serum
25(OH)D3 levels: deficient<20 ng/mL (N=9), insufficient 20 to
31.9 ng/mL (N=24) and sufficient≥32ng/mL (N=17). Panels d, e,
and f show plots (and correlation coefficients) of serum 25(OH)D3
versus 24,25(OH)2D3, 25(OH)D3 versus 1,25(OH)D3, and
24,25(OH)2D3 versus 1,25(OH)D3 levels at baseline and during D3
supplementation. Caption in panel a, also refers to panels b and c
Fig. 2 Time course of the change in serum PTH levels (panel a) and
PBMC 24-hydroxylase activity (panel b) in vitamin D3 deficiency
(filled circle, N=9), insufficient (open circle, N=24), and sufficient
(filled square, N=17) CRC patients receiving 2,000 IU of oral chole-
calciferol daily; panel c shows the baseline and day 90 serum VDBP
levels. Net effects of the cholecalciferol supplementation mediated
changes in plasma vitamin D3 metabolite and VDBP levels were
evaluated by calculating free index of 25(OH)D3 (panel d),
24,25(OH)2D3 (panel e) and 1,25(OH)2D3 (panel f) at baseline and
on day 90 of the D3 supplementation. Free index=molar ratio of
vitamin D3 metabolite/VDBP
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VDBP levels were observed during D3 supplementation
(Fig. 2b and c). Baseline and day 90 serum VDBP levels for
all three vitamin D3 status categories were within the normal
range (200–550 μg/mL). D3 supplementation increased the
free indices of serum 25(OH)D3 and 24,25(OH)2D3 (Fig. 2d
and e); 1,25(OH)2D3 free index did not change (Fig. 2f).
In summary, the significant consequences of D3 supple-
mentation were the decrease in serum PTH levels by day 30,
and increase in 25(OH)D3 levels on days 30 and 90; the
changes in serum of 24,24(OH)2D3, 1,25(OH)2D3 and
VDBP levels and PBMC 24-OHase were not significant at
any of the time points analyzed (Table 2).
Vitamin D SNPs and Serum Vitamin D3 Metabolite Levels
and Risk of Vitamin D3 Insufficiency
Associations between the tag SNPs from the 6 genes (VDR,
GC, CYP2R1, CYP27A1, CYP27B1, and CYP24A1) with
baseline serum levels of 25(OH)D3, 24,25(OH)2D3, and
1,25(OH)2D3 were evaluated in the 313 CRC patients. At
p<0.05, two GC SNPs (rs4588 and rs2282679, in linkage
disequilibrium [LD] with each other, r2=0.98), two
CYP24A1 SNPs (rs2762934 and rs2762939) and one VDR
SNP (rs11168267) were associated with low baseline levels
of at least one serum vitamin D3 metabolite; SNPs associ-
ated with high baseline levels of at least one serum vitamin
D3 metabolite were GC rs222016, CYP24A1 rs111675277
and VDR rs11574077 (Table 3). After multiple testing, only
GC rs4588 remained significantly associated with low base-
line serum 1,25(OH)2D3 levels.
TheGC rs4588 and rs2282679 SNPs were associated with
less increase in serum 25(OH)D3 and 1,25(OH)2D3 levels
after 90 days of D3 supplementation in 50 patients (Table 3).
Six other SNPs, rs10500804 and rs12794714 (CYP2R1),
rs6022999 (CYP24A1) and rs2525044, rs739837,
rs7975232 (VDR) were also associated with low levels of at
least one vitamin D metabolite after supplementation
(Table 3). Only two SNPs were associated with higher serum
vitamin D3 metabolite levels after supplementation (Table 3).
The risk of vitamin D insufficiency in association with
tagSNPs was evaluated in the 313 CRC patients stratified
into 2 groups: vitamin D3 sufficient (reference, baseline
serum 25(OH)D3≥32ng/ml) and vitamin D3 insufficient
(baseline serum 25(OH)D3<32ng/mL). GC rs4588 and
rs2282679 were associated with increased odds of vitamin
D3 insufficiency while GC rs222014 and CYP24A1
rs4809958 and rs6013905 in LD (with r2=1) were associ-
ated with reduced odds of insufficiency (Table 4).
Discussion
In this study, 64.9 % of CRC patients had baseline serum
25(OH)D3 levels less than 32 ng/mL. Similar high percent-
age of vitamin D3 deficient and insufficient individuals have
been reported in healthy controls and patients with acute
myeloid leukemia, colorectal, prostate, and breast cancer in
Western New York [24–26]. Therefore, the high prevalence
of vitamin D3 deficiency in these CRC patients simply
reflects the vitamin D3 status of the general population in
Table 2 Changes in vitamin D3 metabolites and other vitamin D3 related variables measured during D3 supplementation in 50 CRC patients
categorized by vitamin D3 status
Time (days) Changes in serum D3
variables from baseline
Vitamin D3 status p value
Deficient (N=9) Insufficient (N=24) Sufficient (N=17)
30 Δ25(OH)D3 20.6±5.9 15.5±7.8 11.0±9.6 0.009
Δ24,25(OH)2D3 0.8±0.6 0.6±0.6 0.7±1.2 0.80
Δ1,25(OH)2D3 7.5±20.5 6.5±15.1 4.4±18.7 0.9
ΔPTH −35.5±18.2 −15.4±25.0 −16.3±19.9 0.04
ΔPBMC CYP24A1 activity 3.5±10.1 2.0±6.0 −0.3±8.4 0.70
90 Δ25(OH)D3 34.5±11.1 26.3±11.6 13.8±11.3 0.0007
Δ24,25(OH)2D3 1.5±1.0 1.7±1.0 1.3±1.7 0.30
Δ1,25(OH)2D3 23.7±20.9 9.4±20.5 1.0±23.1 0.10
ΔPTH −32.0±14.0 −21.6±29.4 −15.1±23.4 0.20
ΔVDBP 44.4±71.2 −3.4±61.8 −69.3±166.1 0.09
180 Δ25(OH)D3 32.5±14.6 27.5±12.0 21.7±15.4 0.20
Δ24,25(OH)2D3 2.0±1.3 2.3±1.2 2.1±2.0 0.60
Δ1,25(OH)2D3 31.1±19.6 29.3±27.4 12.0±27.0 0.10
ΔPTH −30.3±23.4 −24.1±24.4 −13.3±21.7 0.20
Statistics represent mean±SD. Tests for equality for all the variables between baseline 25(OH)D3 groups at baseline, day 30, 90 and 180 done by
Chi-square tests
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Western New York. As expected, 25(OH)D3 levels were
higher in blood samples collected in summer/fall than in
samples collected in winter/spring. There was no association
between 25(OH)D3 levels and race perhaps because of the
small sample size of Black Americans in this study.
The increase in 25(OH)D3 and decrease in PTH levels
which we observed in all vitamin D3 status categories, is
consistent with prior reports and were expected as physiologic
response to D3 supplementation. However, other reports indi-
cate that D3 supplementation has no effect on serum PTH levels
[27, 28]. These contradictory observations may reflect differ-
ences in D3 supplementation doses utilized, calcium homeo-
stasis related to dietary calcium intake and other calciotropic
hormones. Our data suggest that serum 24,25(OH)2D3, 1,25
(OH)2D3, and VDBP levels are of limited value as measures of
response to D3 supplementation. Changes in serum 25(OH)D3
without associated change in serum 1,25(OH)2D3 levels during
D3 supplements has been reported [29]. Moreover, there is no
difference in baseline serum 24,25(OH)2D3 levels in these
CRC patients (1.4±0.5 ng/mL) and that reported in healthy
controls [30, 31]. This finding suggests that 25(OH)D3-24-
hydroxylation may not play a critical role in the pathogenesis
Table 3 Associations between SNPs in the vitamin D3 pathway genes with serum 25(OH)D3, 24,25(OH)2D3 and 1,25(OH)2D3 levels at baseline
and after 90-days of D3 supplementation
D3 metabolites Gene SNP ID Function Baseline (N=313) After D3 supplementation (N=50)
a
β p valueb β p valueb
25(OH)D3 GC (VDBP) rs4588 Exon/Missense −2.43 0.017 −0.19 0.0009
rs2282679 Intron −2.49 0.015 −0.19 0.0008
rs222016 Intron 2.24 0.035 Not significant
CYP2R1 rs10500804 Intron Not significant −0.13 0.04
rs12794714 Exon/Synonymous −0.13 0.04
rs7129781 Intron 0.23 0.04
CYP24A1 rs111675277 Intron 5.15 0.028 Not significant
VDR rs11168267 Intron −3.59 0.030
24,25(OH)2D3 CYP2R1 rs7129781 Intron Not significant 0.53 0.02
CYP24A1 rs6022999 Intron −0.32 0.02
VDR rs11574077 Intron 0.71 0.023 Not significant
1,25(OH)2D3 GC (VDBP) rs4588 Exon/Missense −4.86 0.0008
c −0.28 0.01
rs2282679 Intron −4.69 0.0012 −0.27 0.02
rs222016 Intron 3.40 0.025 Not significant
CYP24A1 rs2762934 mRNA-untranslated −4.01 0.010
rs2762939 Intron −3.72 0.007
VDR rs2525044 Intron Not significant −0.34 0.007
rs11574077 Intron 0.59 0.01
rs739837 mRNA-untranslated −0.42 0.002
rs7975232 Intron −0.43 0.001
Only significant association (p<0.05) between SNPs and either baseline or day-90 plasma vitamin D3 variables are shown. The only baseline and
day-90 overlapping associations were between GC (rs4855 and rs2282679) with both 25(OH)D3 and 1,25(OH)2D3. SNPs in linkage disequilibrium
[LD]: rs4855/rs2282679 (r2 =0.98), rs10500804/rs12794714 (r2 =1.0) and rs7975232/rs739837 (r2 =0.9). CYP2R1 rs7129781 was associated with
high 25(OH)D3 and 24,25(OH)2D3 levels after D3 supplementation while VDR rs11574077 was associated with high 1,25(OH)2D3 levels
aMost frequent genotype was used as reference and compared with pooled heterozygous and rare genotypes because of small sample size
b Raw p values (not corrected for multiple testing)
c The only significant association after multiple testing
Table 4 Genotype association with vitamin D3 status at baseline
Gene SNPs ID OR (95 % CI) p value
GC rs222014 0.476 (0.27–0.84) 0.009
CYP24A1 rs4809958a 0.570 (0.35–0.92) 0.021
CYP24A1 rs6013905a 0.580 (0.36–0.93) 0.021
GC rs4588b,c 1.65 (1.07–2.58) 0.026
GC rs2282679b 1.65 (1.07–2.58) 0.026
25(OH)D3 reference group is sufficient (coded as zero), 1=deficient+
insufficient; increase in odds of deficient/insufficient for each addition-
al copy of variant allele
a SNPs in linkage disequilibrium [LD] with each other
b SNPs in linkage disequilibrium [LD] with each other
c This SNP is located in an exon, all others are in introns
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of systemic vitamin D3 insufficiency in CRC patients. The use
of serum 24,25(OH)2D3 levels in evaluating the role of 24-
hydroxylase in vitamin D3 status and responses to cholecalcif-
erol supplementation is, however, of limited value because of
its further metabolism, by the same enzyme, to 25(OH)D3-
23,26-lactone and cholecalcoic acid. Whereas, the decrease in
25(OH)D3 is not a useful measure of 24-hydroxylase because it
is also a substrate of non 24-hydroxylase enzymes such as
CYP11A1 [32, 33].
We found two major kinetic differences between the
changes in total and free serum 25(OH)D3, 24,25(OH)2D3,
and 1,25(OH)2D3 levels during D3 supplementation: First,
while the increase in total serum 25(OH)D3 and 24,25
(OH)2D3 levels was biphasic, the increase in total serum
1,25(OH)2D3 levels was linear. Second, free indices of both
25(OH)D3 and 24,25(OH)2D3 increased whereas 1,25
(OH)2D3 free index did not change. These observations sug-
gest that changes in total and free serum 1,25(OH)2D3 levels
were insufficient to trigger changes in PBMC 24-OHase and
serum calcium levels. Free 1,25(OH)2D3 index is the serum
measure highly correlated with hypercalcemia [34]. Although
underlying mechanisms of the kinetic differences in 25(OH)
D3 and 1,25(OH)2D3 changes during D3 supplementation are
unknown, we suggest tight reciprocal regulation of 1,25
(OH)2D3 levels by CYP24A1 and CYP27B1 catalyzed me-
tabolism prevents the increase serum 1,25(OH)2D3 levels.
Differences in the VDBP capacity and binding affinity along
with variations in adipose tissue storage may play a further
role in regulating serum 1,25(OH)2D3 levels. The percentages
of free forms of 25(OH)D3 and 1,25(OH)2D3 in circulation are
0.04 % and 0.4 %, respectively while VDBP affinity for 25
(OH)D3 is 5×10
−8–9.5×10−11M compared to ∼4×10−7M for
1,25(OH)2D3 [35, 36].
Our results show that genetic variants of GC SNPs rs4588
and rs2282679 were associated with low baseline levels of 25
(OH)D3 and 1,25(OH)2D3, with increased odds of vitamin D3
insufficiency and with suboptimal response to D3 supplemen-
tation in CRC patients. These findings are consistent with
previous reports where these same SNPs have been associated
with low serum 25(OH)D3 in both healthy and patients with a
variety of diseases including cancer [7–11] and reduced serum
25(OH)D3 changes after vitamin D3 supplementation in
healthy volunteers [12]. Although, genome wide studies have
associated CYP2R1 SNPs rs10500804 and rs12794714, with
vitamin D levels and vitamin D insufficiency [7, 8] the present
study only showed an association after supplementation.
GC SNP rs222014 and CYP24A1 SNPs rs4809958 and
rs6013905 were associated with reduced risk of vitamin D3
insufficiency, while GC SNPs rs4588 and rs2282679 were
associated with increased risk of insufficiency. However, it
is unclear why GC rs222016 and CYP24A1 rs111675277,
SNPs associated with high 25(OH)D3 levels, were not as-
sociated with reduced risk of D3 insufficiency. Possible
explanations may include differences in statistical analysis
(continuous vs. categorical OR), the character of the colo-
rectal cancer disease itself and/or small sample size. Thus
GC rs222014 and CYP24A1 rs4809958 and rs6013905
SNPs could be potential predictive markers for low risk
vitamin D3 insufficiency, while GC rs4588 and rs2282679
may be both predictive of insufficiency and reduced re-
sponse to D3 supplementation in CRC patients.
In summary, we found that baseline serum 25(OH)D3
levels and polymorphisms in the vitamin D3 pathway genes,
especially in the GC and CYP24A1 genes affect response to
D3 supplementation in CRC patients and are associated with
increased risk of vitamin D3 insufficiency. Further studies, in
large populations, are needed to confirm and determine if
individuals withGC rs4588 or rs2282679 SNPs require higher
doses of D3 supplementation to achieve vitamin D3 sufficiency.
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